A Prognostic Model to Identify Patients with Advanced Pancreas Adenocarcinoma Who Could Benefit from Second-line Chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seung Tae | - |
dc.contributor.author | Choi, Yoon Ji | - |
dc.contributor.author | Park, Kyong Hwa | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.contributor.author | Seo, Jae Hong | - |
dc.contributor.author | Shin, Sang Won | - |
dc.contributor.author | Kim, Jun Suk | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.date.accessioned | 2021-09-06T08:23:27Z | - |
dc.date.available | 2021-09-06T08:23:27Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2012-03 | - |
dc.identifier.issn | 0936-6555 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/105360 | - |
dc.description.abstract | Aims: The role of salvage chemotherapy after first-line therapy in advanced pancreatic cancer has not yet been established. We intended to identify prognostic factors for long-term survival of advanced pancreatic adenocarcinoma patients with second-line chemotherapy and to devise a prognostic model of clinical parameters. Patients and methods: We analysed 90 patients who had received second-line chemotherapy after the failure of first-line therapy in recurrent or metastatic pancreatic adenocarcinoma between August 2003 and December 2008. Results: The median age at the time of second-line chemotherapy was 61.9 years (range 39.8-74.9) and the median Eastern Cooperative Oncology Group (ECOG) performance status was 1 (0-2). Median progression-free survival and overall survival for second-line chemotherapy were 2.1 and 4.5 months, respectively, with an overall response rate of 10%. In multivariate analysis, an ECOG performance status of 2 or more, non-responder for first-line chemotherapy and albumin level of <3.5 mg/dl were independent prognostic factors for decreased overall survival for all 90 patients. Overall survival was estimated based on the number of adverse prognostic factors: zero or one (good prognostic group), two (intermediate group) or three (poor prognostic group). The median overall survival for good (n = 50), intermediate (n = 24) and poor (n = 16) prognostic groups was 5.5, 3.3 and 2.1 months, respectively (P <0.001). Conclusion: Our result suggests that second-line chemotherapy may be beneficial for overall survival in patients with ECOG performance status 0-1, albumin level >= 3.5 mg/dl and response to first-line chemotherapy. (C) 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE LONDON | - |
dc.subject | GEMCITABINE | - |
dc.subject | CANCER | - |
dc.subject | SURVIVAL | - |
dc.subject | OXALIPLATIN | - |
dc.subject | THERAPY | - |
dc.subject | TRIAL | - |
dc.title | A Prognostic Model to Identify Patients with Advanced Pancreas Adenocarcinoma Who Could Benefit from Second-line Chemotherapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Seung Tae | - |
dc.contributor.affiliatedAuthor | Choi, Yoon Ji | - |
dc.contributor.affiliatedAuthor | Park, Kyong Hwa | - |
dc.contributor.affiliatedAuthor | Oh, Sang Cheul | - |
dc.contributor.affiliatedAuthor | Seo, Jae Hong | - |
dc.contributor.affiliatedAuthor | Shin, Sang Won | - |
dc.contributor.affiliatedAuthor | Kim, Jun Suk | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.identifier.doi | 10.1016/j.clon.2011.02.005 | - |
dc.identifier.scopusid | 2-s2.0-84856619954 | - |
dc.identifier.wosid | 000300812900003 | - |
dc.identifier.bibliographicCitation | CLINICAL ONCOLOGY, v.24, no.2, pp.105 - 111 | - |
dc.relation.isPartOf | CLINICAL ONCOLOGY | - |
dc.citation.title | CLINICAL ONCOLOGY | - |
dc.citation.volume | 24 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 105 | - |
dc.citation.endPage | 111 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | GEMCITABINE | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Pancreatic adenocarcinoma | - |
dc.subject.keywordAuthor | prognostic model | - |
dc.subject.keywordAuthor | second-line chemotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.